Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Fridman

Showing results (11-20 of 35) with videos related to

Pageof 4
Sort By:
Plos One|March 24, 2016
A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine CandidatesDhanasekaran Govindarajan, Liming Guan, Steven Meschino, et al.
Oncoimmunology|December 18, 2012
An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platformArthur Fridman, Adam C Finnefrock, Daniela Peruzzi, et al.
Vaccine|August 11, 2011
An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroupsValerian B Pinto, Elizabeth E Moran, Francisco Cruz, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factorsTessie B McNeely, Najaf A Shah, Arthur Fridman, et al.
Journal of Virology|July 15, 2005
High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus controlMiles P Davenport, Lei Zhang, Ansuman Bagchi, et al.
Infectious Diseases and Therapy|November 23, 2023
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT TrialJulie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Infectious Diseases and Therapy|April 25, 2024
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT TrialJulie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Vaccine|October 21, 2018
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stabilityLan Zhang, Eberhard Durr, Jennifer D Galli, et al.
Human Gene Therapy|June 7, 2008
Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacyBarbara Cipriani, Arthur Fridman, Claus Bendtsen, et al.
Journal of Virological Methods|August 26, 2021
Development of a microneutralization assay for HSV-2Melanie S Horton, Michael Minnier, Scott Cosmi, et al.
Pageof 4

Showing results (11-20 of 35) with videos related to

Sort By:
Pageof 4
Plos One|March 24, 2016
A Rapid and Improved Method to Generate Recombinant Dengue Virus Vaccine CandidatesDhanasekaran Govindarajan, Liming Guan, Steven Meschino, et al.
Oncoimmunology|December 18, 2012
An efficient T-cell epitope discovery strategy using in silico prediction and the iTopia assay platformArthur Fridman, Adam C Finnefrock, Daniela Peruzzi, et al.
Vaccine|August 11, 2011
An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroupsValerian B Pinto, Elizabeth E Moran, Francisco Cruz, et al.
Human Vaccines & Immunotherapeutics|December 9, 2014
Mortality among recipients of the Merck V710 Staphylococcus aureus vaccine after postoperative S. aureus infections: an analysis of possible contributing host factorsTessie B McNeely, Najaf A Shah, Arthur Fridman, et al.
Journal of Virology|July 15, 2005
High-potency human immunodeficiency virus vaccination leads to delayed and reduced CD8+ T-cell expansion but improved virus controlMiles P Davenport, Lei Zhang, Ansuman Bagchi, et al.
Infectious Diseases and Therapy|November 23, 2023
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT TrialJulie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Infectious Diseases and Therapy|April 25, 2024
Correction to: Virologic Outcomes with Molnupiravir in Nonhospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT TrialJulie M Strizki, Jay A Grobler, Nicholas Murgolo, et al.
Vaccine|October 21, 2018
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stabilityLan Zhang, Eberhard Durr, Jennifer D Galli, et al.
Human Gene Therapy|June 7, 2008
Therapeutic vaccination halts disease progression in BALB-neuT mice: the amplitude of elicited immune response is predictive of vaccine efficacyBarbara Cipriani, Arthur Fridman, Claus Bendtsen, et al.
Journal of Virological Methods|August 26, 2021
Development of a microneutralization assay for HSV-2Melanie S Horton, Michael Minnier, Scott Cosmi, et al.
Pageof 4